{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:05:25Z","timestamp":1772136325435,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Shanxi Patent Transformation Program","award":["202304011"],"award-info":[{"award-number":["202304011"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>To provide evidence for optimization of multi-kinase inhibitors (MKIs) use in the clinic, we use the public database to describe and evaluate electrolyte disorders (EDs) related to various MKIs treated for renal cell carcinoma. We analyzed spontaneous reports submitted to the Food and Drug Administration Adverse Events Reporting System (FAERS) in an observational and retrospective manner. Selecting electrolyte disorders' adverse events to multikinase inhibitors (axitinib, cabozantinib, lenvatinib, pazopanib, sunitinib, and sorafenib). We used Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and multi-item gamma Poisson shrinker (MGPS) algorithms to analyze suspected adverse reactions of electrolyte disorders induced by MKIs (which were treated for renal cell carcinoma) between January 2004 and December 2022. As of December 2022, 2772 MKIs (which were treated for renal cell carcinoma) ICSRs were related to electrolyte disorders AEs. In general, there were more AEs cases in males, except lenvatinib and 71.8% of the cases were submitted from North America. ICSRs in this study, the age group most frequently affected by electrolyte disorders AEs was individuals aged 45\u201364\u00a0years for axitinib, cabozantinib, pazopanib, and sunitinib, whereas electrolyte disorders AEs were more common in older patients (65\u201374\u00a0years) for sorafenib and lenvatinib. For all EDs documented in ICSRs (excluding missing data), the most common adverse outcome was hospitalization(1429\/2674, 53.4%), and the most serious outcome was death\/life-threat(281\/2674, 10.5%). The prevalence of mortality was highest for sunitinib-related EDs (145\/616, 23.5%), excluding missing data (n\u2009=\u200968), followed by cabozantinib-related EDs (20\/237, 8.4%), excluding missing data (n\u2009=\u20091). The distribution of time-to-onset of Each drug-related ICSRs was not all the same, and the difference was statistically significant (P\u2009=\u20090.001). With the criteria of ROR, the six MKIs were all significantly associated with electrolyte disorders AEs, the strongest association was the association between cabozantinib and hypermagnesaemia. MKIs have been reported to have significant electrolyte disorders AEs. Patients and physicians need to recognize and monitor these potentially fatal adverse events.<\/jats:p>","DOI":"10.1038\/s41598-024-56335-4","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T02:02:09Z","timestamp":1709776929000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Electrolyte disorders induced by six multikinase inhibitors therapy for renal cell carcinoma: a large-scale pharmacovigilance analysis"],"prefix":"10.1038","volume":"14","author":[{"given":"Xianhua","family":"She","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"56335_CR1","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3390\/cancers15020529","volume":"15","author":"RM Paragliola","year":"2023","unstructured":"Paragliola, R. M. et al. Bone metabolism effects of medical therapy in advanced renal cell carcinoma. Cancers (Basel) 15, 529 (2023).","journal-title":"Cancers (Basel)"},{"key":"56335_CR2","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.ctrv.2009.08.004","volume":"35","author":"NP van Erp","year":"2009","unstructured":"van Erp, N. P., Gelderblom, H. & Guchelaar, H.-J. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat. Rev. 35, 692\u2013706 (2009).","journal-title":"Cancer Treat. Rev."},{"key":"56335_CR3","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3390\/ijms18030625","volume":"18","author":"O Ancker","year":"2017","unstructured":"Ancker, O., Wehland, M., Bauer, J., Infanger, M. & Grimm, D. The adverse effect of hypertension in the treatment of thyroid cancer with multi-kinase inhibitors. Int. J. Mol. Sci. 18, 625 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"56335_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.critrevonc.2010.03.006","volume":"78","author":"J Bellmunt","year":"2011","unstructured":"Bellmunt, J., Eisen, T., Fishman, M. & Quinn, D. Experience with sorafenib and adverse event management. Crit. Rev. Oncol. Hematol. 78, 24\u201332 (2011).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"56335_CR5","doi-asserted-by":"publisher","first-page":"250","DOI":"10.7150\/jca.22318","volume":"9","author":"C Balmelli","year":"2018","unstructured":"Balmelli, C. et al. Lenvatinib in advanced radioiodine-refractory thyroid cancer\u2014A retrospective analysis of the Swiss Lenvatinib Named Patient Program. J. Cancer 9, 250\u2013255 (2018).","journal-title":"J. Cancer"},{"key":"56335_CR6","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1530\/ERC-18-0049","volume":"25","author":"AG Gianoukakis","year":"2018","unstructured":"Gianoukakis, A. G., Dutcus, C. E., Batty, N., Guo, M. & Baig, M. Prolonged duration of response in lenvatinib responders with thyroid cancer. Endocr.-Relat. Cancer 25, 699\u2013704 (2018).","journal-title":"Endocr.-Relat. Cancer"},{"key":"56335_CR7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1530\/ERC-18-0258","volume":"26","author":"MI Hu","year":"2019","unstructured":"Hu, M. I. et al. Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer. Endocr.-Relat. Cancer 26, 241\u2013250 (2019).","journal-title":"Endocr.-Relat. Cancer"},{"key":"56335_CR8","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1089\/thy.2017.0356","volume":"28","author":"M Kim","year":"2018","unstructured":"Kim, M. et al. Tertiary care experience of sorafenib in the treatment of progressive radioiodine-refractory differentiated thyroid carcinoma: A Korean Multicenter Study. Thyroid 28, 340\u2013348 (2018).","journal-title":"Thyroid"},{"key":"56335_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/ijms21010010","volume":"21","author":"OV Ancker","year":"2019","unstructured":"Ancker, O. V., Kr\u00fcger, M., Wehland, M., Infanger, M. & Grimm, D. Multikinase inhibitor treatment in thyroid cancer. Int. J. Mol. Sci. 21, 10 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"56335_CR10","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/bjd\/ljad039","volume":"188","author":"A Egeberg","year":"2023","unstructured":"Egeberg, A. & Thyssen, J. P. Increased reporting of cerebrovascular accidents with use of risankizumab observed in the Food and Drug Administration Adverse Events Reporting System (FAERS). Br. J. Dermatol. 188, 793\u2013794 (2023).","journal-title":"Br. J. Dermatol."},{"key":"56335_CR11","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.amjmed.2013.07.021","volume":"126","author":"S Mohan","year":"2013","unstructured":"Mohan, S., Gu, S., Parikh, A. & Radhakrishnan, J. Prevalence of hyponatremia and association with mortality: Results from NHANES. Am. J. Med. 126, 1127-1137e1121 (2013).","journal-title":"Am. J. Med."},{"key":"56335_CR12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s40264-017-0611-5","volume":"41","author":"J Min","year":"2017","unstructured":"Min, J., Osborne, V., Kowalski, A. & Prosperi, M. Reported adverse events with painkillers: Data mining of the US Food and Drug Administration adverse events reporting system. Drug Saf. 41, 313\u2013320 (2017).","journal-title":"Drug Saf."},{"key":"56335_CR13","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1177\/1074248420984082","volume":"26","author":"LN Moreland-Head","year":"2021","unstructured":"Moreland-Head, L. N., Coons, J. C., Seybert, A. L., Gray, M. P. & Kane-Gill, S. L. Use of disproportionality analysis to identify previously unknown drug-associated causes of cardiac arrhythmias using the Food and Drug Administration Adverse Event Reporting System (FAERS) database. J. Cardiovasc. Pharmacol. Ther. 26, 341\u2013348 (2021).","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"issue":"4","key":"56335_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate, A. et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. 54(4), 315\u2013321 (1998).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"56335_CR15","doi-asserted-by":"publisher","first-page":"6576","DOI":"10.1002\/cam4.3198","volume":"9","author":"G Chen","year":"2020","unstructured":"Chen, G. et al. Renal adverse effects following the use of different immune checkpoint inhibitor regimens: A real-world pharmacoepidemiology study of post-marketing surveillance data. Cancer Med. 9, 6576\u20136585 (2020).","journal-title":"Cancer Med."},{"key":"56335_CR16","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1093\/ndt\/gfaa272","volume":"36","author":"H Seethapathy","year":"2021","unstructured":"Seethapathy, H. et al. Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors. Nephrol. Dial. Transplant. 36, 2241\u20132247 (2021).","journal-title":"Nephrol. Dial. Transplant."},{"key":"56335_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1053\/j.ackd.2013.05.005","volume":"21","author":"MH Rosner","year":"2014","unstructured":"Rosner, M. H. & Dalkin, A. C. Electrolyte disorders associated with cancer. Adv. Chronic Kidney Dis. 21, 7\u201317 (2014).","journal-title":"Adv. Chronic Kidney Dis."},{"key":"56335_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/cancers15061851","volume":"15","author":"MA Barbieri","year":"2023","unstructured":"Barbieri, M. A. et al. Neuropsychiatric adverse drug reactions with tyrosine kinase inhibitors in gastrointestinal stromal tumors: An analysis from the European spontaneous adverse event reporting system. Cancers 15, 11 (2023).","journal-title":"Cancers"},{"key":"56335_CR19","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s12094-014-1234-2","volume":"16","author":"R De las Pe\u00f1as","year":"2014","unstructured":"De las Pe\u00f1as, R., Escobar, Y., Henao, F., Blasco, A. & Rodr\u00edguez, C. A. SEOM guidelines on hydroelectrolytic disorders. Clin. Transl. Oncol. 16, 1051\u20131059 (2014).","journal-title":"Clin. Transl. Oncol."},{"key":"56335_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2007.04.016","volume":"19","author":"G Miltiadous","year":"2008","unstructured":"Miltiadous, G., Christidis, D., Kalogirou, M. & Elisaf, M. Causes and mechanisms of acid-base and electrolyte abnormalities in cancer patients. Eur. J. Intern. Med. 19, 1\u20137 (2008).","journal-title":"Eur. J. Intern. Med."},{"key":"56335_CR21","unstructured":"Shirali, A.C. Chapter 5 : Electrolyte and Acid\u2013Base Disorders in Malignancy (2016)."},{"key":"56335_CR22","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1200\/JCO.2008.20.8355","volume":"27","author":"JH Schiller","year":"2009","unstructured":"Schiller, J. H. et al. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: Results from a phase II study. J. Clin. Oncol. 27, 3836\u20133841 (2009).","journal-title":"J. Clin. Oncol."},{"key":"56335_CR23","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/hed.23898","volume":"38","author":"Y Lalami","year":"2016","unstructured":"Lalami, Y. et al. Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and\/or metastatic head and neck cancer. Head Neck 38, 347\u2013354 (2016).","journal-title":"Head Neck"},{"key":"56335_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00280-009-1028-3","volume":"65","author":"T Shimizu","year":"2009","unstructured":"Shimizu, T. et al. Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent d-19575 (glufosfamide) in patients with solid tumors. Cancer Chemother. Pharmacol. 65, 243\u2013250 (2009).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"56335_CR25","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3389\/fonc.2020.00779","volume":"10","author":"I Verzicco","year":"2020","unstructured":"Verzicco, I. et al. Electrolyte disorders induced by antineoplastic drugs. Front. Oncol. 10, 779 (2020).","journal-title":"Front. Oncol."},{"key":"56335_CR26","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1371\/journal.pone.0164794","volume":"11","author":"D Santini","year":"2016","unstructured":"Santini, D. et al. Risk of hyponatraemia in cancer patients treated with targeted therapies: A systematic review and meta-analysis of clinical trials. Plos One 11, 32 (2016).","journal-title":"Plos One"},{"key":"56335_CR27","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1002\/cncr.28766","volume":"120","author":"LD Locati","year":"2014","unstructured":"Locati, L. D. et al. Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic\/pharmacodynamic and quality-of-life assessments. Cancer 120, 2694\u20132703 (2014).","journal-title":"Cancer"},{"key":"56335_CR28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejphar.2016.02.064","volume":"777","author":"G Liamis","year":"2016","unstructured":"Liamis, G., Filippatos, T. D. & Elisaf, M. S. Electrolyte disorders associated with the use of anticancer drugs. Eur. J. Pharmacol. 777, 78\u201387 (2016).","journal-title":"Eur. J. Pharmacol."},{"key":"56335_CR29","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40264-019-00888-1","volume":"43","author":"E Megapanou","year":"2020","unstructured":"Megapanou, E., Florentin, M., Milionis, H., Elisaf, M. & Liamis, G. Drug-induced hypophosphatemia: Current insights. Drug Saf. 43, 197\u2013210 (2020).","journal-title":"Drug Saf."},{"key":"56335_CR30","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.2169\/internalmedicine.0262-17","volume":"57","author":"S Godo","year":"2018","unstructured":"Godo, S. et al. Life-threatening hyperkalemia associated with axitinib treatment in patients with recurrent renal carcinoma. Intern. Med. 57, 2895\u20132900 (2018).","journal-title":"Intern. Med."},{"key":"56335_CR31","doi-asserted-by":"publisher","first-page":"5499","DOI":"10.1128\/MCB.01080-06","volume":"27","author":"M Rahmani","year":"2023","unstructured":"Rahmani, M. et al. The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol. Cell. Biol. 27, 5499\u20135513 (2023).","journal-title":"Mol. Cell. Biol."},{"key":"56335_CR32","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.lungcan.2010.08.004","volume":"70","author":"GM-F Ruinemans","year":"2010","unstructured":"Ruinemans, G.M.-F., Balemans, C., Mattijssen, V., Wiersma-van Tilburg, A. J. & Smit, H. J. M. Fatal necrotizing pancreatitis during combined treatment with erlotinib and sunitinib. Lung Cancer 70, 364\u2013365 (2010).","journal-title":"Lung Cancer"},{"key":"56335_CR33","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/ced.12694","volume":"41","author":"VR Belum","year":"2016","unstructured":"Belum, V. R., Serna-Tamayo, C., Wu, S. & Lacouture, M. E. Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: A meta-analysis. Clin. Exp. Dermatol. 41, 8\u201315 (2016).","journal-title":"Clin. Exp. Dermatol."},{"key":"56335_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/prp2.829","volume":"9","author":"G Liamis","year":"2021","unstructured":"Liamis, G., Hoorn, E. J., Florentin, M. & Milionis, H. An overview of diagnosis and management of drug-induced hypomagnesemia. Pharmacol. Res. Perspect. 9, 23 (2021).","journal-title":"Pharmacol. Res. Perspect."},{"key":"56335_CR35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.amjcard.2005.09.066","volume":"96","author":"L De Luca","year":"2005","unstructured":"De Luca, L. et al. Hyponatremia in patients with heart failure. Am. J. Cardiol. 96, 19\u201323 (2005).","journal-title":"Am. J. Cardiol."},{"key":"56335_CR36","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.semnephrol.2010.09.002","volume":"30","author":"N Lameire","year":"2010","unstructured":"Lameire, N., Van Biesen, W. & Vanholder, R. Electrolyte disturbances and acute kidney injury in patients with cancer. Semin. Nephrol. 30, 534\u2013547 (2010).","journal-title":"Semin. Nephrol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-56335-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-56335-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-56335-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T02:08:05Z","timestamp":1709777285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-56335-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["56335"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-56335-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3402473\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,7]]},"assertion":[{"value":"1 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5592"}}